| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
A reply to “Lung cancer outcomes: Are BMI and race clinically relevant?”
|
Liu, Geoffrey
|
|
|
154 |
C |
p. 225-226
|
artikel
|
| 2 |
A risk stratification scheme for synchronous oligometastatic non-small cell lung cancer developed by a multicentre analysis
|
Spaggiari, Lorenzo
|
|
|
154 |
C |
p. 29-35
|
artikel
|
| 3 |
Association of severe lymphopenia and disease progression in unresectable locally advanced non-small cell lung cancer treated with definitive chemoradiation and immunotherapy
|
Friedes, Cole
|
|
|
154 |
C |
p. 36-43
|
artikel
|
| 4 |
A unique small cell lung carcinoma disease progression model shows progressive accumulation of cancer stem cell properties and CD44 as a potential diagnostic marker
|
Heng, Win Sen
|
|
|
154 |
C |
p. 13-22
|
artikel
|
| 5 |
Breath profile as composite biomarkers for lung cancer diagnosis
|
Zou, Yingchang
|
|
|
154 |
C |
p. 206-213
|
artikel
|
| 6 |
Calculated indices of volatile organic compounds (VOCs) in exhalation for lung cancer screening and early detection
|
Chen, Xing
|
|
|
154 |
C |
p. 197-205
|
artikel
|
| 7 |
Clinical utility of plasma EGFR mutation detection with quantitative PCR in advanced lung cancer: A meta-analysis
|
Kok, Peey-Sei
|
|
|
154 |
C |
p. 113-117
|
artikel
|
| 8 |
Coexistence of a novel RGS18 downstream intergenic region ALK fusion and a THUMPD2-ALK fusion in a lung adenocarcinoma patient and response to crizotinib
|
Wang, Yan-li
|
|
|
154 |
C |
p. 216-218
|
artikel
|
| 9 |
Contents
|
|
|
|
154 |
C |
p. v-vii
|
artikel
|
| 10 |
Controversies and challenges in the pathologic examination of lung resection specimens after neoadjuvant treatment
|
Weissferdt, Annikka
|
|
|
154 |
C |
p. 76-83
|
artikel
|
| 11 |
Corrigendum to “Inhibition of IGF1R enhances 2-deoxyglucose in the treatment of non-small cell lung cancer” [Lung Cancer 123 (2018) 36–43]
|
Liu, Fakeng
|
|
|
154 |
C |
p. 227
|
artikel
|
| 12 |
Corrigendum to “Re-expression of LKB1 in LKB1-mutant EKVX cells leads to resistance to paclitaxel through the up-regulation of MDR1 expression” [Lung Cancer 88/2 (2015) 131–138]
|
Mao, Kaisheng
|
|
|
154 |
C |
p. 228
|
artikel
|
| 13 |
Corrigendum to “Short communication: Diagnosis of lung cancer increases during the annual southeast Asian haze periods” [Lung Cancer 113 (2017) 1–3]
|
Hassan, A.
|
|
|
154 |
C |
p. 229
|
artikel
|
| 14 |
Dose-dependence in acquisition of drug tolerant phenotype and high RYK expression as a mechanism of osimertinib tolerance in lung cancer
|
Ohara, Shuta
|
|
|
154 |
C |
p. 84-91
|
artikel
|
| 15 |
Editorial Board
|
|
|
|
154 |
C |
p. iii
|
artikel
|
| 16 |
Examination of factors associated with lymph node metastases in lung carcinoids: Results from a single institution retrospective cohort study
|
Pathipati, Mythili P.
|
|
|
154 |
C |
p. 186-194
|
artikel
|
| 17 |
First-in-human study of inhaled Azacitidine in patients with advanced non-small cell lung cancer
|
Cheng, Haiying
|
|
|
154 |
C |
p. 99-104
|
artikel
|
| 18 |
Impact of subsequent immune checkpoint inhibitor treatment on overall survival with avelumab vs docetaxel in platinum-treated advanced NSCLC: Post hoc analyses from the phase 3 JAVELIN Lung 200 trial
|
Park, Keunchil
|
|
|
154 |
C |
p. 92-98
|
artikel
|
| 19 |
KRAS G12C-mutated advanced non-small cell lung cancer: A real-world cohort from the German prospective, observational, nation-wide CRISP Registry (AIO-TRK-0315)
|
Sebastian, Martin
|
|
|
154 |
C |
p. 51-61
|
artikel
|
| 20 |
Lung cancer outcomes: Are BMI and race clinically relevant?
|
Braillon, Alain
|
|
|
154 |
C |
p. 224
|
artikel
|
| 21 |
Lung cancer prediction by Deep Learning to identify benign lung nodules
|
Heuvelmans, Marjolein A.
|
|
|
154 |
C |
p. 1-4
|
artikel
|
| 22 |
Lung cancer research and its citation on clinical practice guidelines
|
Pallari, Elena
|
|
|
154 |
C |
p. 44-50
|
artikel
|
| 23 |
Lymphatic drainage of lung cancer follows an intersegmental pathway within the visceral pleura
|
Fourdrain, Alex
|
|
|
154 |
C |
p. 118-123
|
artikel
|
| 24 |
MET exon 14 skipping mutation positive non-small cell lung cancer: Response to systemic therapy
|
Wong, Selina K.
|
|
|
154 |
C |
p. 142-145
|
artikel
|
| 25 |
PARD3-ALK: A novel ALK fusion gene identified in a patient with lung adenocarcinoma
|
Yang, Liangwei
|
|
|
154 |
C |
p. 219-220
|
artikel
|
| 26 |
Preoperative chest computed tomography evaluation for predicting intraoperative lung resection strongly depends on interpreters experience
|
Collaud, Stephane
|
|
|
154 |
C |
p. 23-28
|
artikel
|
| 27 |
Regulation of immune microenvironment may enable MET-altered NSCLC patients to benefit from immune checkpoint inhibitors
|
Zhang, Chenyue
|
|
|
154 |
C |
p. 221-223
|
artikel
|
| 28 |
Revealing the BRD4-NOTCH3 fusion: A novel hill in the cancer landscape
|
Costa, Fabiano de Almeida
|
|
|
154 |
C |
p. 146-150
|
artikel
|
| 29 |
Safety and efficacy of first-line dacomitinib in Asian patients with EGFR mutation-positive non-small cell lung cancer: Results from a randomized, open-label, phase 3 trial (ARCHER 1050)
|
Cheng, Ying
|
|
|
154 |
C |
p. 176-185
|
artikel
|
| 30 |
Serum soluble mesothelin-related protein (SMRP) and fibulin-3 levels correlate with baseline malignant pleural mesothelioma (MPM) tumor volumes but are not useful as biomarkers of response in an immunotherapy trial
|
Katz, Sharyn I.
|
|
|
154 |
C |
p. 5-12
|
artikel
|
| 31 |
Solid subtype predicts early bone metastases in sensitive EGFR-mutated lung adenocarcinoma patients after surgery
|
Xiong, Anning
|
|
|
154 |
C |
p. 124-130
|
artikel
|
| 32 |
Strategies to overcome resistance to immune checkpoint blockade in lung cancer
|
Attili, Ilaria
|
|
|
154 |
C |
p. 151-160
|
artikel
|
| 33 |
Survival analysis for non-squamous NSCLC patients harbored STK11 or KEAP1 mutation receiving atezolizumab
|
Shang, Xiaoling
|
|
|
154 |
C |
p. 105-112
|
artikel
|
| 34 |
Targeting rare and non-canonical driver variants in NSCLC – An uncharted clinical field
|
Volckmar, Anna-Lena
|
|
|
154 |
C |
p. 131-141
|
artikel
|
| 35 |
The evolving landscape of biomarker testing for non-small cell lung cancer in Europe
|
Kerr, Keith M.
|
|
|
154 |
C |
p. 161-175
|
artikel
|
| 36 |
The role for chemotherapy in 80 years and older patients with metastatic non-small cell lung cancer: A National cancer database analysis
|
Ahmed, Zaheer
|
|
|
154 |
C |
p. 62-68
|
artikel
|
| 37 |
The source of the tumor tissue should be taken into consideration when distinguishing tumor mutational burden scores
|
Zhang, Chenyue
|
|
|
154 |
C |
p. 214-215
|
artikel
|
| 38 |
Tumor cell proliferation (Ki-67) expression and its prognostic significance in histological subtypes of lung adenocarcinoma
|
Li, Zhihua
|
|
|
154 |
C |
p. 69-75
|
artikel
|
| 39 |
Where the nose is going to help the eye: Sniffing lung cancer
|
Lamote, Kevin
|
|
|
154 |
C |
p. 195-196
|
artikel
|
Tijdschrift beschrijving